topic

176 Evaluating the safety of tumor treating fields (TTFields) application to the torso – in vivo studies
Shiri Davidi, Roni Blat, Mijal Munster, Anna Shteingauz, Shay Cahal, Moshe Giladi, Uri Weinberg, Yoram Palti, Moshe Giladi

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A105; DOI: 10.1136/jitc-2020-SITC2020.0176
177 A severe cytokine release syndrome with respiratory failure in recurrent mesothelioma induced by EpCAM CAR-T cells infusion: a case report
Sitong Wang, Juemin Fang, Hui Wang, Qing Xu

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A105; DOI: 10.1136/jitc-2020-SITC2020.0177
179 Immunotherapy trials lack a biomarker for inclusion: implications for drug development
Jacob Adashek, Alexey Goloubev, Shumei Kato, Razelle Kurzrock

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A106; DOI: 10.1136/jitc-2020-SITC2020.0179
183 Overcoming immunotherapy resistance in T cell-inflamed lung cancer
Brendan Horton, Brendan Horton, Duncan Morgan, Noor Momin, Vidit Bhandarkar, Dane Wittrup, Chris Love, Stefani Spranger

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A108-A109; DOI: 10.1136/jitc-2020-SITC2020.0183
181 Anlyasis of therapeutic effect and safty of PD-1 inhibitors in clinical treatment of oral and maxillofacial malignant tumors
Haochuan Liu, Yaqiong Jie, Xinguang Han

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A108; DOI: 10.1136/jitc-2020-SITC2020.0181
21 Plasma-based proteomic profiling as a tool for predicting response to immunotherapy in melanoma patients
Michal Harel, Coren Lahav, Eyal Jacob, Eran Issler, Haim Bar, Adam Dicker, Ofer Sharon, Antonietta Bacchiocchi, Ruth Halaban, Mario Sznol, Yuval Shaked

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A11-A12; DOI: 10.1136/jitc-2020-SITC2020.0021
189 A clear increase in TILs and modest tumor growth inhibition by pembrolizumab in prostate cancer tumors growing in bone of CD34+ engrafted NOG mice
Suominen Suominen, Justyna Zdrojewska, Jenni Mäki-Jouppila, Philip Dube, Ivan Gladwyn-Ng, Paul Volden, Jukka Rissanen, Mari Suominen

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A111-A112; DOI: 10.1136/jitc-2020-SITC2020.0189
193 Differences in thyroid immune-related adverse events between lung cancer types, a retrospective analysis
Rahim Jiwani, Heather Brody, Yuxuan Mao, Elisabeth Lee, Rita Rehana, Cynthia Cherry, Hui Bian, Praveen Namireddy

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A114; DOI: 10.1136/jitc-2020-SITC2020.0193
200 NBTXR3 nanoparticle with immunoradiation improves survival and generates long-term anti-tumor memory in an anti-PD1 resistant murine lung cancer model
Yun Hu, James Welsh, Sebastien Paris, Hampartsoum Barsoumian, Chike Abana, Saumil Gandhi, Quynh Nguyen, Maria Cortez

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A117-A118; DOI: 10.1136/jitc-2020-SITC2020.0200
199 Enhanced immune responses in human breast and colon cancer following checkpoint therapy in a CD34⁺ stem cell humanized NCG (HuCD34NCG) mouse model
Christoph Eberle, Jenny Rowe, Ann Fiore, Robert Mihalek, Stephen Festin

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A117; DOI: 10.1136/jitc-2020-SITC2020.0199

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages